ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.772,85
0,50%
S&P 500
5.222,68
0,16%
Dow Jones
39.512,84
0,32%
Euro vs US Dollar
1,07885
0,00%
Bitcoin
60.889,31
0,15%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. BioLineRx Ltd (BLRX)

  7. BioLineRx Ltd (BLRX) News

BLRX

BioLineRx (BLRX)

BioLineRx Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BLRX
DatumZeitQuelleÜberschriftSymbolFirma
06/05/202413h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
17/04/202413h00PR Newswire (US)BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual MeetingNASDAQ:BLRXBioLineRx Ltd
04/03/202413h47Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
28/02/202413h08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
16/02/202413h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
08/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BLRXBioLineRx Ltd
29/12/202322h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BLRXBioLineRx Ltd
29/12/202322h15Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:BLRXBioLineRx Ltd
21/12/202313h05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
12/12/202313h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
20/11/202313h03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
20/11/202312h25IH Market NewsMonday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and moreNASDAQ:BLRXBioLineRx Ltd
01/11/202312h43PR Newswire (Canada)BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
31/10/202314h00PR Newswire (US)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
31/10/202314h00PR Newswire (Canada)BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. VenturesNASDAQ:BLRXBioLineRx Ltd
26/10/202320h18Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:BLRXBioLineRx Ltd
18/10/202323h07AllPennyStocks.comNew Collaboration Could Revolutionize Treatment of Chronic Spinal Cord InjuriesNASDAQ:BLRXBioLineRx Ltd
12/10/202313h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
28/09/202313h11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
11/09/202313h07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
11/09/202313h00PR Newswire (US)BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple MyelomaNASDAQ:BLRXBioLineRx Ltd
30/08/202313h16IH Market NewsWednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and moreNASDAQ:BLRXBioLineRx Ltd
30/08/202313h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
30/08/202312h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
08/08/202323h25Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
17/07/202313h10Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
23/06/202322h17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
24/05/202313h07Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
25/04/202313h08Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
17/04/202317h09Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
 Showing the most relevant articles for your search:NASDAQ:BLRX

Kürzlich von Ihnen besucht

BIT
UI381C
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten